UnitedHealth Group
UNH
$414.40
-1.68%
UnitedHealth Group is one of the largest private health insurers globally, providing medical benefits to approximately 51 million members through employer-sponsored, self-directed, and government-backed insurance plans, while its Optum franchises offer healthcare services spanning pharmacy benefits, outpatient care, and data analytics. As a dominant player in the managed care industry, the company's scale and vertical integration create a formidable competitive moat. The current investor narrative centers on the company's operational recovery from a challenging 2025, with a strong rebound in Q1 2026 earnings and an 80% rally off its lows, though an unresolved DOJ investigation and reliance on government reimbursement rates introduce uncertainty.…
UNH
UnitedHealth Group
$414.40
Related headlines
Investment Opinion: Should I buy UNH Today?
Rating: Hold. UnitedHealth is a high-quality defensive stock with a strong recovery underway, but the unresolved DOJ investigation and premium valuation warrant caution. The analyst consensus is Buy with an average target of $475.23, implying 13% upside, but the wide dispersion of targets ($313-$529) reflects high uncertainty.
Supporting Evidence: The Q1 2026 earnings rebound (net income $6.28B, net margin 5.62%) shows operational improvement. Free cash flow of $19.67B provides a strong financial cushion. The forward P/E of 18.75x is reasonable relative to the industry median of ~20x, and the PEG ratio based on forward estimates is ~1.0, indicating fair value. Revenue growth is decelerating (1.96% YoY), but the Optum segment offers higher-margin growth potential. The stock has outperformed the S&P 500 by 34.6% over the past year, confirming strong relative strength.
Risks & Conditions: The biggest risks are the DOJ investigation outcome and government reimbursement rate changes. This Hold would upgrade to Buy if the DOJ investigation is resolved favorably and the stock pulls back to a forward P/E below 17x, or if revenue growth re-accelerates above 5%. It would downgrade to Sell if the DOJ investigation leads to material fines or if government rates are cut significantly. Overall, UNH appears fairly valued relative to its history and peers, with the forward P/E in line with the sector.
Sign up to view all
UNH 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on UnitedHealth Group's 12-month outlook, with a consensus price target around $475.23 and implied upside of +14.7% versus the current price.
Average Target
$475.23
0 analysts
Implied Upside
+14.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$313 - $529
Analyst target range
UnitedHealth is covered by 26 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.59 (where 1 is Strong Buy and 5 is Sell). The average target price is $475.23, implying approximately 13% upside from the current price of $420.74. The distribution leans bullish, with a majority of analysts rating it Buy or Overweight, and no Sell ratings in the recent institutional ratings data. The target price range spans from a low of $313.00 to a high of $529.00, indicating a wide dispersion of views. The high target of $529.00 assumes continued operational improvement, margin expansion, and potential resolution of regulatory overhangs, while the low target of $313.00 reflects risks such as a prolonged DOJ investigation, adverse government policy changes, or a recession impacting medical costs. Recent ratings from firms like TD Cowen (Hold), Truist (Buy), and Morgan Stanley (Overweight) suggest a generally positive but cautious sentiment. The wide spread between low and high targets (69% difference) signals high uncertainty around the stock's future, which is typical for a company facing regulatory and policy risks.
Drowning in data?
Find the real signal!
Bulls vs Bears: UNH Investment Factors
UnitedHealth presents a mixed picture: a strong operational rebound in Q1 2026, robust free cash flow, and a consensus Buy rating with 13% upside are countered by decelerating revenue growth, a premium valuation, and an unresolved DOJ investigation. The bull case currently has slightly stronger evidence given the earnings recovery and analyst support, but the bear case is significant due to regulatory overhang and policy dependence. The single most important tension is whether the DOJ investigation resolves favorably and whether government reimbursement rates remain supportive—these factors will determine if the stock can sustain its rally or face a correction.
Bullish
- Strong Q1 2026 Earnings Rebound: Net income surged to $6.28 billion in Q1 2026 from just $10 million in Q4 2025, with net margin recovering to 5.62% from 0.01%. This demonstrates a sharp operational recovery and improved medical cost management.
- Robust Free Cash Flow Generation: Trailing twelve-month free cash flow stands at $19.67 billion, providing ample liquidity for debt service, dividends, and share buybacks. This financial strength supports a dividend yield of 2.64%.
- Analyst Consensus Buy with 13% Upside: 26 analysts rate UNH a Buy with a mean recommendation score of 1.59 (1=Strong Buy). The average target price of $475.23 implies ~13% upside from the current $420.74, with a high target of $529.
- Defensive Characteristics with Low Beta: With a beta of 0.63, UNH is 37% less volatile than the market, making it a defensive holding. The stock has outperformed the S&P 500 by 34.6% over the past year, showing strong relative strength.
Bearish
- Unresolved DOJ Investigation Overhang: The ongoing DOJ investigation creates legal and regulatory uncertainty. Recent news highlights that this unresolved issue makes the risk-reward less attractive despite the operational recovery.
- Decelerating Revenue Growth: Q1 2026 revenue grew only 1.96% YoY to $111.7 billion, down from 2.9% in Q1 2025 and 10.7% in Q1 2024. This deceleration reflects a maturing core insurance business and potential headwinds from government reimbursement rates.
- Premium Valuation vs. Industry Peers: The trailing P/E of 24.95x is at a 25% premium to the industry median of ~20x. While the forward P/E of 18.75x is more reasonable, the current valuation leaves limited margin of safety.
- Dependence on Government Policy: A significant portion of revenue comes from Medicare and Medicaid, making UNH highly sensitive to government reimbursement rates and policy changes. Recent better-than-expected Medicare rates boosted the stock, but future changes could reverse gains.
UNH Technical Analysis
UnitedHealth is in a sustained uptrend, with the stock up 51.0% over the past year, significantly outperforming the S&P 500's 16.5% gain. The current price of $420.74 sits at 91.2% of its 52-week range (low $234.60, high $461.62), indicating strong momentum but also proximity to resistance near the high. This positioning suggests the stock is in a mature uptrend, where further upside may require a catalyst to break through the 52-week high. Short-term momentum is accelerating: the 1-month change of +3.7% and 3-month change of +18.5% both exceed the S&P 500's respective gains of 0.8% and 3.5%, confirming bullish relative strength. The 1-month relative strength of +2.9% versus the market indicates the stock is gaining momentum, though the 1-year relative strength of +34.6% shows the long-term trend is firmly in favor of UnitedHealth. The 52-week low of $234.60 provides a key support level, while the 52-week high of $461.62 acts as resistance. A breakout above $461.62 would signal a continuation of the uptrend and potentially open the door to new highs, while a breakdown below $234.60 would be a severe bearish signal. With a beta of 0.63, the stock is 37% less volatile than the market, making it a relatively defensive holding within the healthcare sector, which is attractive for risk-averse investors.
Beta
0.63
0.63x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$235-$462
Price range past year
Annual Return
+66.1%
Cumulative gain past year
| Period | UNH Return | S&P 500 |
|---|---|---|
| 1m | -2.8% | +0.2% |
| 3m | +12.4% | +3.7% |
| 6m | +44.4% | +8.0% |
| 1y | +66.1% | +18.2% |
| ytd | +23.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UNH Fundamental Analysis
Revenue growth has been steady but decelerating: Q1 2026 revenue of $111.7 billion grew only 1.96% year-over-year, down from the 2.9% growth in Q1 2025 and the 10.7% growth in Q1 2024. The UnitedHealthcare segment generated $82.99 billion in revenue, while OptumHealth contributed $4.58 billion, highlighting the dominance of the insurance business. The deceleration reflects a maturing core business and potential headwinds from government reimbursement rates, though the Optum segment offers higher-margin growth opportunities. Profitability improved sharply in Q1 2026, with net income of $6.28 billion and a net margin of 5.62%, rebounding from the Q4 2025 trough where net income was just $10 million (net margin 0.01%). Gross margin in Q1 2026 was 22.74%, up from 16.34% in Q4 2025, indicating a recovery in medical cost management. However, the operating margin of 8.05% remains below the 9.23% level seen in Q3 2024, suggesting room for further improvement. The balance sheet is solid: debt-to-equity of 0.83 is manageable, and free cash flow for the trailing twelve months is $19.67 billion, providing ample liquidity. The current ratio of 0.79 is below 1.0, typical for insurers, but the strong operating cash flow of $8.91 billion in Q1 2026 covers debt service comfortably. ROE of 12.8% is healthy, though down from historical levels above 20%, reflecting the earnings volatility in 2025.
Quarterly Revenue
$111.7B
2026-03
Revenue YoY Growth
+2.0%
YoY Comparison
Gross Margin
22.7%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UNH Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. The trailing P/E is 24.95x, while the forward P/E is 18.75x, implying the market expects significant earnings growth in the coming year. The gap between trailing and forward P/E suggests analysts anticipate a sharp recovery in earnings, which is consistent with the Q1 2026 rebound. Compared to the industry average (Medical - Healthcare Plans), the stock's trailing P/E of 24.95x is at a premium to the sector median of approximately 20x, representing a 25% premium. This premium is partially justified by UnitedHealth's market leadership and scale, but the forward P/E of 18.75x is more in line with the sector, indicating that the market is pricing in the earnings recovery. Historically, UnitedHealth's trailing P/E has ranged from 9.8x (Q1 2026) to 33.3x (Q3 2025), with the current 24.95x near the middle of this band. The current P/E is below the 5-year average of roughly 22x, suggesting the stock is not overvalued relative to its own history, especially considering the expected earnings rebound. The PEG ratio of -1.62 is negative due to negative earnings growth in the trailing period, but forward estimates imply a PEG of around 1.0, which is reasonable.
PE
25.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 19x~29x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UnitedHealth's financial risks center on earnings volatility and margin pressure. Net income swung from $6.29 billion in Q1 2025 to just $10 million in Q4 2025, with net margins collapsing from 5.74% to 0.01% before recovering to 5.62% in Q1 2026. The debt-to-equity ratio of 0.83 is manageable, but the current ratio of 0.79 is below 1.0, typical for insurers but still a liquidity concern. Revenue growth is decelerating, with Q1 2026 growth of only 1.96% YoY, down from 10.7% two years prior, indicating a maturing core business. The company's heavy reliance on government programs (Medicare/Medicaid) exposes it to reimbursement rate changes, which directly impact profitability.
Market & Competitive Risks: The stock's trailing P/E of 24.95x trades at a 25% premium to the industry median of ~20x, leaving it vulnerable to valuation compression if earnings disappoint. With a beta of 0.63, UNH is less volatile than the market, but it is not immune to sector rotation or macro headwinds. The unresolved DOJ investigation creates regulatory uncertainty that could lead to fines or operational restrictions. Recent news indicates a market rotation from tech to value, which could benefit UNH as a defensive healthcare stock, but any adverse policy changes (e.g., cuts to Medicare Advantage rates) would directly impact revenue and margins.
Worst-Case Scenario: In a severe adverse scenario, the DOJ investigation results in significant fines or operational changes, coupled with unfavorable government reimbursement rate cuts and a recession that increases medical costs. This could drive the stock down to its 52-week low of $234.60, representing a 44% decline from the current price of $420.74. The analyst low target of $313.00 implies a 26% downside, while the historical max drawdown of -29.98% suggests a potential loss of about 30% from current levels.
FAQ
The primary risk is the unresolved DOJ investigation, which could result in fines or operational restrictions, potentially impacting earnings and stock price. Second, the company's heavy reliance on government reimbursement rates (Medicare/Medicaid) exposes it to policy changes; a 1% cut in rates could materially reduce revenue. Third, medical cost spikes, as seen in Q4 2025 when net income fell to $10 million, highlight the volatility in the insurance business. Finally, decelerating revenue growth (1.96% YoY) suggests the core business is maturing, and failure to accelerate growth through Optum could lead to multiple compression.
The 12-month outlook is cautiously optimistic, with a base case (55% probability) targeting $420-$475, driven by gradual operational recovery and stable margins. The bull case (25% probability) sees the stock reaching $475-$529 if the DOJ investigation resolves favorably and growth accelerates. The bear case (20% probability) targets $313-$380 if regulatory or policy headwinds materialize. The analyst average target of $475.23 implies ~13% upside from the current price of $420.74. The most likely scenario is the base case, assuming the DOJ investigation remains unresolved but does not escalate.
UnitedHealth's trailing P/E of 24.95x is at a 25% premium to the industry median of ~20x, suggesting it is slightly overvalued relative to peers. However, the forward P/E of 18.75x is in line with the sector, indicating the market expects earnings growth to justify the premium. Historically, UNH's trailing P/E has ranged from 9.8x to 33.3x, with a 5-year average of ~22x, so the current level is near the middle. The PEG ratio based on forward estimates is ~1.0, which is reasonable. Overall, the stock appears fairly valued, with the premium justified by its market leadership and scale, but there is limited margin of safety.
UnitedHealth offers a compelling risk/reward for long-term investors, with a consensus Buy rating and 13% upside to the average analyst target of $475.23. The stock's low beta (0.63) and strong free cash flow ($19.67B) provide a defensive cushion, while the Q1 2026 earnings rebound (net margin 5.62%) signals operational recovery. However, the unresolved DOJ investigation and decelerating revenue growth (1.96% YoY) introduce uncertainty. For investors with a 3-5 year horizon, UNH is a good buy at current levels, especially on any pullback below $400. Short-term traders may find limited upside given the stock's proximity to its 52-week high of $461.62.
UnitedHealth is best suited for long-term investment, given its defensive characteristics (beta 0.63), consistent dividend payments (yield 2.64%), and strong free cash flow. The stock has low volatility relative to the market, making it less attractive for short-term traders seeking quick gains. The 52-week range of $234.60 to $461.62 suggests significant price swings, but the long-term trend is upward. A minimum holding period of 3-5 years is recommended to ride out regulatory and earnings volatility. Short-term traders may find opportunities around earnings announcements or DOJ news, but the stock's low beta limits short-term profit potential.
